Tazarotene Supply in 2026: A Provider Briefing

Tazarotene — a third-generation topical retinoid with FDA approvals for plaque psoriasis, acne vulgaris, and photoaging — has seen intermittent supply disruptions that are affecting patient access across the country. While not formally listed on the FDA Drug Shortage Database, the real-world availability picture is more nuanced than official listings suggest.

This briefing covers what prescribers need to know about Tazarotene supply, prescribing implications, cost considerations, and tools to help your patients maintain continuity of care.

Current Supply Timeline

Tazarotene supply has been uneven since late 2024, with periodic tightening across several formulations:

• Generic Tazarotene cream 0.1% — Intermittent availability from major wholesalers (McKesson, Cardinal Health, AmerisourceBergen). Limited number of ANDA holders contributing to supply fragility.
• Generic Tazarotene gel 0.05% and 0.1% — Generally more available than cream, though regional gaps persist.
• Brand-name Tazorac — Allergan/AbbVie continues to manufacture but pharmacy stocking has declined as formularies shift to generics.
• Fabior foam 0.1% — Limited distribution; many pharmacies do not carry it routinely.

The underlying drivers are structural rather than acute: a small number of generic manufacturers, specialized raw material sourcing, and pharmacy ordering algorithms that deprioritize low-volume specialty medications.

Prescribing Implications

The inconsistent supply has several practical implications for clinical practice:

Formulation Flexibility

When writing Tazarotene prescriptions, consider specifying whether formulation substitution is acceptable. A patient prescribed cream 0.1% may find gel 0.1% readily available. Key considerations:

• Cream — Preferred for patients with dry or sensitive skin; more emollient base
• Gel — Better suited for oily skin; may cause more initial drying
• Foam (Fabior) — Lightweight vehicle; good compliance for acne patients but limited availability

Clinically, the active ingredient and concentration are identical across formulations. Vehicle differences primarily affect tolerability and patient preference.

Therapeutic Alternatives

When Tazarotene is unavailable, evidence-based alternatives include:

• For acne vulgaris:
  • Tretinoin 0.025%–0.1% (cream, gel, microsphere) — extensive evidence base, widely available generic
  • Adapalene 0.1%–0.3% (gel, cream, lotion) — 0.1% available OTC; less irritating; good first-line option
  • Trifarotene 0.005% cream (Aklief) — selective RAR-gamma agonist; uniquely indicated for trunk acne; brand-only
• For plaque psoriasis:
  • Calcipotriene 0.005% (cream, ointment, solution) — vitamin D analog; first-line topical for mild-moderate psoriasis
  • Calcipotriene/betamethasone dipropionate (Enstilar, Taclonex) — combination product; strong evidence for plaque psoriasis
  • Topical corticosteroids — appropriate for short-term management; consider potency relative to body site
• For photoaging:
  • Tretinoin 0.025%–0.05% cream — gold standard for photodamage; extensive long-term data

For a patient-facing comparison, you can direct patients to our alternatives guide.

Availability Picture by Channel

Understanding where Tazarotene is available helps when advising patients:

• Chain pharmacies (CVS, Walgreens, Rite Aid) — Stocking is algorithm-driven; locations with low Tazarotene volume may not carry it. Patients may need to check multiple locations.
• Independent pharmacies — Often have relationships with multiple wholesalers and greater ordering flexibility. A valuable option for patients in underserved areas.
• Mail-order/specialty pharmacy — Broader inventory; may have stock when local pharmacies don't. Many insurance plans offer 90-day supply options.
• Compounding pharmacies — Can prepare Tazarotene in custom concentrations or vehicles when commercial products are unavailable (requires compounding-specific prescription).

Cost and Access Considerations

Cost remains a significant barrier to Tazarotene access, independent of supply:

• Generic Tazarotene: $40–$150 cash price (30–45g tube)
• Brand Tazorac: $250–$600 cash price
• Fabior foam: $400–$700 cash price

Insurance coverage varies widely:

• Most commercial plans cover generic Tazarotene but frequently require prior authorization
• Step therapy requirements are common — plans may require trial of Adapalene or Tretinoin before approving Tazarotene
• Some plans exclude brand-name Tazorac or Fabior entirely, or place them on specialty tiers
• Medicare Part D coverage varies by plan; many require PA

Patient assistance options include manufacturer copay cards (Allergan/AbbVie for Tazorac), GoodRx and SingleCare discount cards for generic, and patient assistance foundations for uninsured patients. Direct patients to our savings guide or see our provider-specific resource on helping patients save on Tazarotene.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers real-time pharmacy stock checking that can be integrated into your patient workflow. When a patient reports difficulty finding Tazarotene, you or your staff can quickly identify pharmacies with current availability and direct the prescription accordingly.

Proactive Prescribing Tips

• Include a note on prescriptions: "May substitute cream for gel or gel for cream if prescribed formulation unavailable" (where clinically appropriate)
• Send prescriptions electronically to the pharmacy with confirmed stock
• For prior authorization denials, document medical necessity including prior treatment failures
• Consider writing a backup prescription for an alternative retinoid that patients can fill if Tazarotene remains unavailable

Patient Education Resources

Share these resources with patients who are having difficulty:

• How to find Tazarotene in stock near you
• Tazarotene shortage update for patients
• Tazarotene side effects guide

Looking Ahead

Several developments may improve the Tazarotene supply landscape in 2026 and beyond:

• Additional ANDA filings for generic Tazarotene could bring new manufacturers to market
• FDA has prioritized addressing drug shortage root causes through manufacturing quality initiatives
• Digital pharmacy tools are making it easier for patients and providers to navigate availability gaps

However, the structural issues — few manufacturers, niche market, complex synthesis — are unlikely to resolve quickly. Providers should plan for continued intermittent availability and maintain familiarity with therapeutic alternatives.

Final Thoughts

Tazarotene remains an important medication in the dermatologic armamentarium, with a unique combination of approvals across acne, psoriasis, and photoaging. The current supply situation requires prescribers to be proactive: flexible with formulations, prepared with alternatives, and equipped with tools to help patients find available stock.

Medfinder for Providers can help streamline this process for your practice. For a practical workflow guide, see our companion article on helping patients find Tazarotene in stock.